en · de · es · fr · pt
sr9009-notes.peptides4800.com › Wiki › Sr9009 Background And Receptor Mechanism — Beginner to Advanced

Sr9009 Background And Receptor Mechanism — Beginner to Advanced

By Editorial Desk · published 2026-02-28 · last reviewed 2026-04-17 · Wiki

circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Background and Receptor Pharmacology

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Related pages on this site

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Supporting material

=== Associated conditions === Women with PMOS have an increased risk of a range of metabolic, cardiovascular, reproductive and mental health conditions. The likelihood of developing metabolic disorders is about three to seven times higher than in women without PMOS. Insulin resistance is common, even in lean women with PMOS. Overweight or obese women with PMOS are at higher risk of type 2 diabetes than women without PMOS at the same BMI. Lean women with PMOS do not appear to be at higher risk of developing diabetes. Other metabolic and cardiovascular complications commonly associated with PMOS include:

==== Others ==== Alfatradiol (Avicis, Avixis, Ell-Cranell Alpha, Pantostin) – oral – alopecia – dual weak estrogen and 5α-reductase inhibitor Minoxidil/finasteride (MorrF) – topical – alopecia – combination of minoxidil (potassium channel opener) and finasteride (5α-reductase inhibitor) Nepidermin (Easyef; DWP-401) – topical – alopecia – recombinant human epidermal growth factor (rhEGF) or epidermal growth factor receptor (EGFR) agonist

=== Opinion polls === A Harvard CAPS/Harris poll from 1–2 October found that 71% of respondents supported the US destroying boats trafficking drugs from South America. A Reuters/Ipsos poll from 7–12 November found that 51% of Americans opposed "killing suspected drug traffickers abroad without judicial process", while 29% supported it.

In chemistry, biochemistry and environmental sciences, deuterium is used as a non-radioactive, stable isotopic tracer, for example, in the doubly labeled water test. In chemical reactions and metabolic pathways, deuterium behaves somewhat similarly to ordinary hydrogen (with a few chemical differences, as noted). It can be distinguished from normal hydrogen most easily by its mass, using mass spectrometry or infrared spectrometry. Deuterium can be detected by femtosecond infrared spectroscopy, since the mass difference drastically affects the frequency of molecular vibrations; 2H–carbon bond vibrations are found in spectral regions free of other signals. Measurements of small variations in the natural abundances of deuterium, along with those of the stable heavy oxygen isotopes 17O and 18O, are of importance in hydrology, to trace the geographic origin of Earth's waters. The heavy isotopes of hydrogen and oxygen in rainwater (meteoric water) are enriched as a function of the temperature of the region where the precipitation falls (and thus enrichment is related to latitude). The relative enrichment of the heavy isotopes in rainwater (as referenced to mean ocean water), when plotted against temperature falls predictably along a line called the global meteoric water line (GMWL). This plot allows samples of precipitation-originated water to be identified along with general information about the climate in which it originated.

Sources: en.wikipedia.org

Notes from published material

=== Dedicated magnet schools === Dedicated magnet schools are offered in the PGCPS system at the PreK-8th grade, elementary and middle school level only. As of 2012-13, Glenarden Woods and Heather Hills are the only full elementary-level dedicated magnet schools in the system. Dedicated magnet schools are "whole school" programs and differ from traditional comprehensive schools, as (1) all students at the school are enrolled and receive instruction in the magnet program and (2) traditional attendance areas for assigning students to a school are replaced by much larger geographical attendance zones, usually split between north county (areas north of Central Avenue) and south county (areas south of Central Avenue). Whole school, dedicated magnet programs are offered through the Creative and Performing Arts, French Immersion, Montessori, and Talented & Gifted Center magnet programs. Students receive specialized instruction that varies from the typical comprehensive program, offered at most other schools. Students are selected for the magnet programs through a magnet lottery for the French Immersion and Montessori programs and also for the Creative and Performing Arts program at the elementary school level. Acceptance into the Creative and Performing Arts program is through audition only at the middle school level. Acceptance into the TAG Centers at Glenarden Woods and Heather Hills Elementary Schools is through specialized TAG testing only.

== Structure == Juncturae tendinum are narrow bands of connective tissues that extend between the tendons of the extensor digitorum communis and the extensor digiti minimi. It is classified into three distinct types (Type 1, 2 and 3) depending on morphology.

Glycogen storage disease type V (GSD5, GSD-V), also known as McArdle's disease, is a metabolic disorder, one of the metabolic myopathies, more specifically a muscle glycogen storage disease, caused by a deficiency of myophosphorylase. Its incidence is reported as one in 100,000, roughly the same as glycogen storage disease type I. The disease was first reported in 1951 by British physician Brian McArdle of Guy's Hospital, London.

== Uses == Although edible and choice, this mushroom is not commercially cultivated on account of its fast maturing and short shelf life. Care is needed to distinguish it from poisonous species. There have been cases (notably in France) in which the deadly Amanita virosa was consumed by individuals who mistook it for this species. Additionally, specimens collected from lawns could be contaminated by pesticides or other chemicals. Culinary uses include eating it sauteed or fried, in sauces, or even sliced raw and included in salads. In flavor and texture, this mushroom is similar to the white button mushroom (A. bisporus) available in grocery stores in most Western countries.

== Prognosis == As of 2012, the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%. This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form. The major scleroderma-related causes of death are: pulmonary hypertension, pulmonary fibrosis, and scleroderma renal crisis. People with scleroderma are also at a heightened risk for developing osteoporosis and for contracting cancer (especially liver, lung, haematologic, and bladder cancers). Scleroderma is also associated with an increased risk of cardiovascular disease. According to a study of an Australian cohort, between 1985 and 2015, the average life expectancy of a person with scleroderma increased from 66 years to 74 years (the average Australian life expectancy increased from 76 to 82 years in the same period).

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Network